Research map: Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany

Back to the article

Papers in this map

  1. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults · Edward E. Walsh · 2023 · 683 citations · Cited by this paper
  2. Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0–14 years in Jiangsu Province, China · 2026 · Related
  3. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom · Douglas Fleming · 2015 · 253 citations · Cited by this paper
  4. Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit–cost analysis · 2026 · Related
  5. Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis · John M. McLaughlin · 2022 · 235 citations · Cited by this paper
  6. Progress toward an Epstein-Barr virus vaccine · 2026 · Related
  7. Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults · Kelsey S Ivey · 2018 · 199 citations · Cited by this paper
  8. Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit–cost analysis · 2026 · Related
  9. Self-Reported Population Health: An International Perspective Based on EQ-5D · Ágota Szende · 2013 · 197 citations · Cited by this paper
  10. Pneumococcal conjugate vaccines in older adults and immunocompromised individuals · 2025 · Related
  11. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community · B. Ultsch · 2015 · 119 citations · Cited by this paper
  12. Healthcare professionals’ perspectives and preferences regarding adolescent meningococcal disease vaccination in the United States · 2026 · Related
  13. Impfen bei Immundefizienz · Tim Niehues · 2017 · 98 citations · Cited by this paper
  14. Whole cell and acellular pertussis vaccines - rethinking the evidence · 2026 · Related
  15. Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States · Mark H. Rozenbaum · 2023 · 94 citations · Cited by this paper
  16. The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study · 2026 · Related
  17. Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study) · Ann Regina Falsey · 2021 · 66 citations · Cited by this paper
  18. Not so cold! Improving the thermostability of mRNA vaccines · 2025 · Related
  19. Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons · Edward E. Walsh · 2025 · 60 citations · Cited by this paper
  20. Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO’s behavioral and social drivers of vaccination framework · 2026 · Related
  21. Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post‐discharge assessed by Respiratory Intensity and Impact Questionnaire · Ann Regina Falsey · 2021 · 57 citations · Cited by this paper
  22. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease · Diana Mendes · 2022 · 56 citations · Cited by this paper
  23. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults · Zhuxin Mao · 2022 · 52 citations · Cited by this paper
  24. Mortality and readmission in the year following hospitalization for pneumonia among US adults · Ahuva Averin · 2021 · 50 citations · Cited by this paper
  25. Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019 · Aleksandra Polkowska · 2024 · 45 citations · Cited by this paper
  26. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019) · Patricia Niekler · 2023 · 44 citations · Cited by this paper
  27. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons · Diya Surie · 2025 · 44 citations · Cited by this paper
  28. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany · Felicitas Kühne · 2023 · 29 citations · Cited by this paper
  29. Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults · Mats Christian Højbjerg Lassen · 2025 · 27 citations · Cited by this paper
  30. RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations · Marylyn M. Addo · 2023 · 23 citations · Cited by this paper
  31. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany · Ahuva Averin · 2024 · 23 citations · Cited by this paper
  32. National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific · Mark A. Fletcher · 2024 · 21 citations · Cited by this paper
  33. Prevalence of chronic conditions and influenza vaccination coverage rates in Germany: Results of a health insurance claims data analysis · Oliver Damm · 2022 · 20 citations · Cited by this paper
  34. Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention – a global challenge from a local perspective · Mine Durusu Tanrıöver · 2025 · 18 citations · Cited by this paper
  35. Incidence of pneumonia in nursing home residents in Germany: results of a claims data analysis · Alexander Maximilian Fassmer · 2018 · 12 citations · Cited by this paper
  36. Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany · Arijita Deb · 2022 · 12 citations · Cited by this paper
  37. The Burden of Respiratory Syncytial Virus (RSV) in Germany: A Comprehensive Data Analysis Suggests Underdetection of Hospitalisations and Deaths in Adults 60 Years and Older · Stefan Michael Scholz · 2024 · 12 citations · Cited by this paper
  38. Clinical and economic inpatient burden of respiratory syncytial virus (RSV) infections in children < 2 years of age in Germany, 2014–2019: a retrospective health claims analysis · Caroline Lade · 2024 · 9 citations · Cited by this paper
  39. Economic burden of respiratory syncytial virus in adults in Germany – a health claims analysis between 2015 and 2018 · Bennet Huebbe · 2024 · 8 citations · Cited by this paper

Source: OpenAlex (CC0)